A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Krystal Biotech, Inc. KRYS

Strong broader-coverage candidate · Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most

On FrontierLab's discovery record since 2026-08-04 (2 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Strong" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-05), not the curated Frontier signal.

Key quality signals

Revenue growth (YoY)	22.6%
Gross margin	93.3%
Gross profits / assets	0.27
Rule of 40	67.5
Net margin	44.9%
Cash runway (months)	—
PEG	0.7
Price / sales	21.7

Quality checklist

✓ Revenue growth — 22.6% (pass ≥ 20%)
~ Gross profits / assets — 0.27 (pass ≥ 0.33)
✓ Gross margin — 93.3% (pass ≥ 60%)
✓ Cash generation
~ Share dilution — 3.1%

Fundamentals — snapshot as of 2026-08-05

Stage	Established
Share issuance (YoY)	3.1% · modest issuance
Moat	—
TAM	—
P/E (trailing)	40.7
EPS (trailing)	$7.98
Burn multiple	—
Gross-margin trend (pts)	-0.1
Cash / assets	0.56
Net debt / EBITDA	-1.9
Statements as of	Q2 FY2026 · filed 2026-08-03

Momentum context — a snapshot from 2026-08-05, not current

Price at surface	$324.77 (as of 2026-08-05)
52-week range	$131 – $382.535
% off 52-wk high	-15.1%
RSI (14)	43
Relative volume	0.8×

Risk flags

Hyper-expansion — assets up ~32% in a year; aggressive expanders have historically lagged.

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-08-05 (end-of-day). How grades are computed →